In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy ...

BEST1 gene therapy is designed to address mutations in the BEST1 gene which is associated with retinal degeneration. We expect that a Phase 1/2 study will be initiated in 2025. The pipeline also ...

Here’s how it works. Scientists have discovered a gene variant that could make some parents more likely to have girls than boys. In the new study, researchers analyzed the genomes of around ...

The others include another gene therapy program, called OPGx-BEST1, and two Phase 3 trials for the company's partnered eye drop solution. And the company has the cash to see these readouts through ...

Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, forming a leading biotech company focused on gene therapies for ... including trials for LCA5, BEST1, and other ophthalmic ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and can ...

Oct. 28, 2024 — Using state-of-the-art technology, researchers have identified several specific steps needed for CRISPR to become active and perform its gene editing function. These preclinical ...

How Is Gene Expression Regulated? The amounts and types of mRNA molecules in a cell reflect the function of that cell. In fact, thousands of transcripts are produced every second in every cell.

Internal and external environmental factors, like gender and temperature, influence gene expression. Sex-limited traits are also autosomal. Unlike sex-influenced traits, whose expression differs ...

The most advanced gene therapy candidate ... the initial patients of the OPGx-BEST1 Phase 1/2 trial, the LYNX-2 Phase 3 trial, and the VEGA-3 Phase 3 trial. The LYNX-2 Phase 3 trial in patients ...

Gene Park is a reporter for The Washington Post, covering video games and gaming culture. He joined The Post in 2015 as audience editor, and is a former reporter in the West Coast and Pacific region.

The merger creates a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of IRDs. In connection with the merger, the combined company ...